ReviewClinical cancer research : an official journal of the American Association for Cancer Research2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Immunotherapy or Targeted Therapy Versus Best Supportive Care for Advanced Gastric Cancer: A Systematic Review and Meta-analysis of Randomized Trials.Journal of gastrointestinal cancer · 2025Pooled it
- Evolving or immutable - phase I solid tumor trials in the era of precision oncology.Investigational new drugs · 2024Pooled it
- Use of geriatric assessment in cancer clinical trials: A systematic review.Journal of geriatric oncology · 2022Pooled it
- Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Meaning-centered pain coping skills training for patients with metastatic cancer: Results of a randomized controlled pilot trial.Psycho-oncology · 2023Trial
- Progress and challenges in expanding access to clinical trials in pancreatic cancer.Communications medicine · 2026Review
- Effect of patient factors and quality of life on ECOG assignment and inter-rater agreement in hospitalized cancer patients.The oncologist · 2026Observational
- An operational target trial emulation framework for causal inference using electronic health record data.NPJ digital medicine · 2026Review
- Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective Study.JTO clinical and research reports · 2026Article
- Artificial intelligence for clinical trial design, conduct, and analysis: a narrative review.ESMO real world data and digital oncology · 2026Review
- A novel prognostic nomogram for elderly renal cell carcinoma patients with lung metastases.Scientific reports · 2026Article
- The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non-small cell lung cancer.Journal of the National Cancer Institute · 2026Article
- Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial.JTO clinical and research reports · 2025Article
- Association between physical activity, performance scores, and clinical trial enrollment in cancer survivors.BMC cancer · 2025Article
- Article
- Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009-2023).European journal of cancer (Oxford, England : 1990) · 2025Article
- Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.Oncotarget · 2025Article
- Laryngeal Cancer in the West of Scotland 2014-2020: Trends and Survival in a Cohort of 867 Patients.The Laryngoscope · 2025Article
- Comparison of baseline patient characteristics in phase 1 and phase 2/3 clinical trials for anticancer treatments.Journal of translational medicine · 2025Article
- Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 13 institutions in 2 countries.
Funding
Abstract
purposePerformance status (PS) is one of the most common eligibility criteria. Many trials are limited to patients with high-functioning PS, resulting in important differences between trial participants and patient populations with the disease. In addition, existing PS measures are subjective and susceptible to investigator bias. EXPERIMENTAL
designA multidisciplinary working group of the American Society of Clinical Oncology and Friends of Cancer Research evaluated how PS eligibility criteria could be more inclusive. The working group recommendations are based on a literature search, review of trials, simulation study, and multistakeholder consensus. The working group prioritized inclusiveness and access to investigational therapies, while balancing patient safety and study integrity.
resultsBroadening PS eligibility criteria may increase the number of potentially eligible patients for a given clinical trial, thus shortening accrual time. It may also result in greater participant diversity, potentially reduce trial participant and patient disparities, and enable clinicians to more readily translate trial results to patients with low-functioning PS. Potential impact on outcomes was explored through a simulation trial demonstrating that when the number of Eastern Cooperative Oncology Group PS2 participants was relatively small, the effect on the estimated HR and power was modest, even when PS2 patients did not derive a treatment benefit.
conclusionsExpanding PS eligibility criteria to be more inclusive may be justified in many cases and could result in faster accrual rates and more representative trial populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.